Europe Dendritic Cell Cancer Vaccines Market Research Report – Segmented By Product Type, End User & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Size, Share, Trends, Growth, Forecasts ( 2024 to 2029)

Updated On: June, 2024
ID: 5267
Pages: 145

Europe Dendritic Cell Cancer Vaccines Market Size (2024 to 2029)

As Per the Report, The Europe dendritic cell cancer vaccines market is forecasted to grow at a robust CAGR of 11.23% from 2024 to 2029.

The intensification of research and development activities related to dendritic cell vaccines is expected to accelerate the growth of the European dendritic cell cancer vaccines. The vaccine can attack multiple cancers, making them practical for various targets. Many clinical trials are looking at dendritic cell cancer vaccines to help many patients. Genetically engineered dendritic cell cancer vaccines are more important tools for treating incurable cancers, such as brain cancer. Being the most malignant of CNS tumors, Glioblastoma shows an average incidence of 3.5 to 5 for every 100,000 people per year in the European region.

Oncologists believe that this market will likely present considerable lucrative opportunities due to the unmet demand for safe and effective cancer treatments with fewer side effects and innate dendritic cell benefits.

Approvals by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medical Board will drive the market. In addition, the increasing prevalence of cancer across Europe will lead to the commercial success of single dendritic cell vaccines. For example, more than 75,000 and 125,000 people are projected to be affected by renal cell carcinoma in the U.S. and Europe, respectively, which will lead to great success in the Rocapuldencel-T in the future.

Withdrawal of the vaccines from clinical trials will significantly hamper the studied market later. More than 70% of these vaccine candidates are currently in the development phase of clinical trials. Additionally, there are some risks and side effects associated with the vaccination method. For example, different types of cancer have a point of origin and have unique mechanisms that show various complications before researchers can develop large-scale treatments. In addition, dendritic cells are adaptable can be modified and formulated depending on the type of antibody accompanying the tumor; this significantly increases the cost for investment for manufacture and production of the vaccine.

This research report on the Europe Dendritic Cell Cancer Vaccines Market has been segmented and sub-segmented into the following categories

By Product Type:

  • CreaVax
  • Sipuleucel-T (Provenge)

By End User:

  • Pediatrics
  • Adults

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

The U.K dendritic cell cancer vaccines market is estimated to be a dominant region in the European dendritic cell cancer vaccines market, with the increasing prevalence of cancer in the said region. Europe has only one-eighth of the world population. However, it has 3.85 million new patients per year, more than a quarter of the total cancer cases recorded. In addition, 1 in every 69 British men and 1 in every 65 British women will be diagnosed with a brain, central nervous system, or intracranial tumor at some point in their lives. 3% of brain and central nervous system tumors in the U.K. are preventable. Hence, the increased awareness of cancer, especially brain cancer, may lead to increased demand for dendritic cell cancer vaccines and thus is projected to drive the growth of the overall market.

Other European regions like Germany, Sweden, Norway, and France are also expected to have a steady growth rate due to increased awareness and favorable reimbursement policies.

KEY MARKET PLAYERS

Prominent Companies leading the Europe Dendritic Cell Cancer Vaccines Market Profiled in the Report are 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation (Dendreon Corporation). Other players in the market include Elios Therapeutics. ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck & co, Northwest Biotherapeutics, Glaxo Smith Kline, ImmunoCellular Therapeutics, Tella Incorporation, and Vaxil BioTherapeutics.,

Please wait. . . . Your request is being processed

Anil Kumar P is research manager at Market Data Forecast and responsible for Healthcare Domain.

Author

Anil Kumar P (Research Manager - Healthcare)

Anil Kumar P is the lead author of this report and the manager of the team responsible for authoring healthcare reports at Market Data Forecast. He holds a Bachelor’s degree in Pharmacy (Hons.) from BITS Pilani, one of India’s premier institutions. Over the past seven years, Anil has gained extensive experience working with multiple market research companies, where he has collaborated with a diverse range of clients—from innovative startups to Fortune 500 companies—delivering data-driven insights and strategic advice that drive business growth.

Read More

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample